(Q38004092)

26 August 2017

title

Taking the negative view of current migraine treatments: the unmet needs (English)

1 reference

Peer Carsten Tfelt-Hansen

26 August 2017

1 reference

2

Jes Olesen

0 references

series ordinal

1

object named as

Peer Tfelt-Hansen

1 reference

26 August 2017

publication date

1 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

375-382

1 reference

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Maximum effect of triptans in migraine? A comment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Over-the-counter triptans for migraine : what are the implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

The acute treatment of episodic and chronic migraine in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Early treatment of migraine with rizatriptan: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Propranolol in the management of recurrent migraine: a meta-analytic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Migraine prophylaxis with divalproex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Divalproex sodium in migraine prophylaxis: a dose-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

New drugs in migraine treatment and prophylaxis: telcagepant and topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

What do patients with migraine want from acute migraine treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Cost of disorders of the brain in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Migraine prevalence, disease burden, and the need for preventive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Finding new drug targets for the treatment of migraine attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Prostaglandin E2(PGE2) induces headache in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630590-000000000-00000

An instrument to assess patient perceptions of satisfaction with acute migraine treatment (EXPERT Study)

21 January 2018

1 reference

12 December 2020

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group

1 reference

12 December 2020

Neurobiology of migraine

1 reference

12 December 2020

Treatment of Acute Migraine With Subcutaneous Sumatriptan

1 reference

12 December 2020

Guidelines for controlled trials of drugs in migraine: second edition

1 reference

12 December 2020

The cost of headache disorders in Europe: the Eurolight project

1 reference

12 December 2020

Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine

1 reference

12 December 2020

Depressogenic effects of medications: a review

1 reference

12 December 2020

Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group

1 reference

12 December 2020

Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control

1 reference

12 December 2020

10.2165/11630590-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1025334055

0 references

1 reference